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Growth hormone and nutrition interact to regulate expressions of
kidney IGF-I and IGFBP mRNAs. The effects of growth hormone (GH)
and fasting on renal insulin-like growth factor-I (IGF-I) and IGF-binding
proteins (IGFBP)-1, -2, -3, -4, -5 were examined in spontaneous dwarf rats
(SDR) which have a complete and specific lack of GH among pituitary
hormones. Renal expression of the mRNA which encodes IGF-I was
reduced in these rats, and IGFBP-1 and IGFBP-4 were found to be
elevated. Administration of GH restored expression of IGF-I and
IGFBP-1 mRNA, suggesting that GH is, among other pituitary hormones,
more specifically associated with renal expression of these genes. The
elevation in the IGFBP-4 mRNA level, however, was not attenuated by
GH administration, indicating that this hormone may not be directly
related to the regulation of expression of this gene. Fasting for 48 hours
resulted in a reduction of IGF-I mRNA and an increase in IGFBP-1
mRNA in SDRs as well as in normal rats, suggesting that a cause other
than a reduced serum GH is responsible for these fasting-induced
changes. Fasting resulted in little change in levels of other IGFBP-2, -3, -4,
-5 mRNAs. When these results were compared with those obtained using
liver, IGFBP mRNA expression was shown to be regulated differently in
different tissues. Based on our finding that IGFBP-1 modulates the
mitogenic action of IGF-I, a full understanding of nutrition-related growth
processes in the kidney must take this relationship into consideration as
well as that which exists between GFI and IGF-I.
Since compensatory renal growth (CRG) seems to contribute,
at least in part, to progressive renal injury leading to glomerulo-
sclerosis [1], we decided to advance our understanding of this
disease by investigating the pathogenesis of CRG. The kidney is a
well known production site of growth hormone (GH)-stimulated
insulin-like growth factor-I (IGF-I) [2, 3], which has been shown
to play an important role in CRG [4, 5]. In addition, we have
previously shown that calorie restriction ameliorated progressive
renal injury in 5/6 nephrectomized rats associated with inhibition
of renal production of IGF-I [6]. Since IGF-I is bound to
IGF-binding proteins (IGFBP5), the actions of IGF-I should be
considered together with those of IGFBPs. It has been shown that
IGFBPs are important modulators of the biological actions of
IGF-I [7, 8]. Six distinct IGFBPs have been isolated to date and
their structures determined by cDNA cloning [9]. The majority of
circulating IGFs are part of a large 150 kDa ternary complex
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consisting of IGFBP-3, an acid-labile subunit, and IGF itself. The
other forms of IGFBPs (BP-1, 2, 4, 5, 6), found mainly in
extracellular fluids or interstitium, are of lower molecular weight,
and act locally to regulate IGF actions [8, 9]. Recently, we showed
that GH and fasting affect expression of IGFBP mRNA as well as
that of IGF-I mRNA in liver [10]. Despite the fact that GH
contributes to glomerulosclerosis probably through IGF-I [3, 11],
the manner in which GH alters IGFBP mRNA in the kidney has
not been explained. Furthermore, much of our knowledge of the
roles of GH and IGF-I has been obtained using hypophysecto-
mized rats as a GH deficient model [12—14]. This model, however,
lacks several other trophic hormones which could also be capable
of modulating IGF-I or IGFBP gene expression. In contrast, the
spontaneous dwarf rat (SDR) lacks GH only due to a mutation in
the GH gene [15, 16]. It is therefore believed to be a better model
for studying the effect of changes in GH levels on renal IGF-I and
IGFBP expression.
In the present study, we examined IGF-I and IGFBP-1, 2, 3, 4,
5 mRNA expression in kidneys of spontaneous GH-deficient
dwarf rats (SDR) before and after GH administration in addition
to changes in expression in this organ as a result of a 48 hours
fasting.
Methods
SDR (dr) rats were supplied by the Roussel Morishita Co. Ltd.
(Shiga, Japan), and housed in a light (14 hours of lighting per day)
and temperature (22°C) controlled room with free access to tap
water and food. These rats were obtained by mating affected
parents (dr/dr). In addition to the 19 adult SDRs (8 weeks old,
mean initial body wt 64 g), 12 age-matched male Sprague-Dawley
rats (SD) were also used which were purchased from CLEA Japan
Inc. (Tokyo, Japan). The animals were divided into two groups,
one for studying the effect of GH (11 female SDRs) and the other
for studying the effect of fasting (8 male SDRs).
Effect of GH
SDRs received twice daily injections of 0.15 mg ovine GH for
five days (NIDDK oGH, supplied by the National Hormone and
Pituitary Program, Baltimore, MD, USA). Ovine GH supplied as
a lyophilized powder was dissolved in 0.03 M NaHCO3/0.9% NaC1
(pH 9.2) containing 1 mg/ml of bovine serum albumin (BSA), and
stored at —80°C. The GH was prepared daily by diluting a stock
solution with saline. Control SDR animals received vehicle injec-
tions for five days. The animals were sacrificed six hours after the
65
F -w
S
IGFBP—1
IGFBP—4
IGFBP—5
IG FBP—2
IGFBP—3
'eQ
66 Kobayashi et at: IGF-I and IGFBPs mRNA in GH deficiency
IG F—I
I
Actin
I
Actin
CL
I
Actin
Actin
I
Actin
Fig. 1. Northem blotting analysis of IGF-I and IGF binding proteins mRNA expression in kidney of spontaneous dwarf rats (SDR5) with (SDR GH) or
without (SDR saline) GH administration for 5 days compared with normal SD rats.
last injection. This experiment was carried out using three groups:
normal (SD rats), SDR, and SDR+GH. In addition, in order to
examine the acute effect of GH, a single injection of oGH (0.75
mg) was given and SDRs were sacrificed six hours later. Kidneys
were removed from these animals under light ether anesthesia
and used for RNA extraction. Experiments were carried out twice
on a different day, and each was performed in duplicate or
triplicate. The mRNA data were obtained for each group of four
to six SDR or SD rats.
Effect of fasting
SDRs were subjected to fasting conditions or fed normally for
two days with free access to tap water. The control SD rats were
either fasted or fed normally for two days. The SDRs and normal
SD rats of the groups which were fed were allowed access to water
only for two hours before sacrifice. The four groups studied were
as follows: normal control, normal fasted, SDR control, and SDR
fasted. Experiments were carried out twice on a different day and
each experiment was performed in duplicate.
Northern blot analysis
The animals were sacrificed under light ether anesthesia and
kidneys were removed rapidly and stored at —80°C prior to RNA
extraction. The extraction was carried out as described previously
[16, 17]. Poly A+ RNA was isolated using oligo-dT cellulose
(Sigma, St. Louis, MO, USA). The RNA was separated on a 1%
agarose gel containing formalin and transferred onto a nylon
membrane (Hybond N; Amersham, Arlington Heights, IL, USA)
by capillary action. The blot was prehybridized in a mixture of
50% formamide, 6xSSC (1xSSC = 150 mi's NaCl/15 mt sodium
citrate, pH 7.0), 0.5% sodium dodecyl sulfate (SDS), 0.1% each of
polyvinyipyrollidone, Ficoll and BSA, and 0,1 mg/mi of sheared
denatured herring sperm DNA, at 42°C for two hours. The blot
was then incubated in a fresh mixture of the same composition
containing 2 to 5 x 106 cpm/ml of 32P-Iabeled probe. After 20
hours incubation, the blots were washed three times for 10
minutes with 2xSSC/0.1% SDS at room temperature and then
with 0.1xSSC/0.1% SDS at 65°C for one hour. They were then
exposed to Kodak XAR-2 film at —80°C for 1 to 14 days. When
the chicken actin eDNA probe was used for hybridization, the
final wash was carried out at 45°C in the same buffer as described
above.
cDNA probes
Rat IGF-I cDNA [18] (prigfl—1, 0.5 kb insert) was supplied by
Dr. Graeme I. Bell (Howard Hughes Medical Institute, The
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Fig. 2. Changes in relative abundance of IGF-I,
IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, and
IGFBP-5 mRNAs in notmal SD rats (E), SDRs
(El small speckled) and GH-treated SDRs
(SDR+GH, El large dots). * P < 0.05 vs.
normal SD rats. Values were corrected based
on amount of actin mRNA.
University of Chicago, Chicago, IL, USA). The cDNA of rat
IGFBPs were the gifts from Dr. D'Ercole (University of North
Carolina, Chapel Hill, NC, USA), and had been obtained by
amplification from rat liver eDNA by the polymerase chain
reaction and cloned into plasmid Bluescript [19]. The cDNA
inserts were excised from the vector by appropriate enzyme
digestion and purified by agrose gel electrophoreses. The
IGFBP-1 (355 bp), IGFBP-2 (360 bp), IGFBP-3 (430 bp),
IGFBP-4 (321 bp) and IGFBP-5 (651 bp) cDNA probes contained
the sequence corresponding to the coding region of bp 436—79 1
[20], bp 613—959 [21], bp 328—755 [22], bp 503—703 [23] and bp
558-1201 [24] of each respective cDNA. The random priming
method was used for 32P-labeling using the reagents obtained
from Amersham. The specific activity of the labeled probes was
between 0.5 and 1 X io cpm/ig DNA.
Quantification of the relative abundance of the mRNA
Blots hybridized to 32P-labeled probes were analyzed using a
bioimaging analyzer (BAS-2000, Fuji Film, Tokyo, Japan) for
quantification of radioactivity of each mRNA. Blots were then
exposed to X-ray film (XAR-5, Kodak, Rochester, NY, USA) at
—80°C for 2 to 14 days.
Statistical analysis
All data were expressed means SE. Tests performed consisted
of Student's t-test and, for multiple comparisons, one way analysis
of variance followed by Student-Newman-Keuls. A P value of less
than 0.05 was considered statistically significant.
Results
Effect of GH treatment on renal IGF—I and IGFBP gene
expression in SDR
After five days of GH administration, body weight increased by
16.8 1.3 g in the experimental group, whereas no significant
weight gain was observed in the SDRs which had received vehicle
alone.
Northern blot analysis of renal poly(A) RNA revealed that
IGF-I mRNA is heterogenous with respect to the size, which
ranged between 0.7 and 7.5 kb. All these IGF-I mRNA subclasses
were consistently seen both in SDRs and in normal rats (Fig. 1).
Quantitative analyzes showed a decreased IGF-I mRNA level in
the SDR (°°30% of the normal rat, Fig. 2). GH treatment of
SDRs for six hours increased IGF-I mRNA up to 49% of normals
(data not shown) and for five days induced a marked increase in
the IGF-I mRNA level which became fully normalized. In addi-
tion, the IGFBP-1 mRNA level in SDR rats was found to have
increased to 180%, compared to that of normal rats. GH treat-
ment of SDRs for six hours decreased 147% of normals (data not
shown) and GH treatment for five days lowered IGFBP-l mRNA
level to a fully normalized level (Figs. 1 and 2). Although
IGFBP-4 mRNA in SDRs increased to a level comparable to that
of IGFBP-1 mRNA, GH treatment had no effect on the IGFBP-4
mRNA level in SDR rats (Figs. 1 and 2). The IGFBP-2 and
IGFBP-3 mRNA levels in SDRs were found to be almost normal
and repeated chronic GH administrations failed to produce any
change (Figs. 1 and 2). IGFBP-5 mRNA showed a tendency to
increase, but did not reach a statistically significant level (P =
0.14), and furthermore it was unaffected by Gil treatment.
Effect of fasting on IGF-I and IGFBP mRNA levels
Fasting for 48 hours resulted in a reduction in renal IGF-I
mRNA levels in SDRs as well as in normal rats. Although the
baseline IGF-I mRNA level was about three times less in the
SDRs than in normal rats, no difference was seen in the degree of
reduction induced by fasting between the normal and SDR group
(42% and 45% reduction, respectively; Figs. 3 and 4). In contrast,
fasting induced a threefold increase in IGFBP-1 mRNA level of
normal rats, compared to that of normally fed rats. In the SDR,
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Fig. 3. Northern blotting analysis of IGF-I and IGF binding proteins mRNA
C, control (normally fed); F, fasted 48 hours.
IGFBP-1 mRNA also increased by 50% with fasting (Figs. 3 4);
however, IGFBP-2, 3, 4, 5 mRNA levels did not, as was also the
case with normal rats (Figs. 3 and 4).
Discussion
Evidence has been accumulating which suggests that GH [25],
IGF-I [26], and insulin [131 are influential in regulating concen-
trations of circulating IGFBPs. In spite of much known about
regulators of serum IGFBPs, there is a lack of information
regarding the role of GH-dependence of renal IGFBPs, which can
regulate the local action of IGF-I.
We have demonstrated that the expression of mRNA encoding
IGF-I, IGFBP-1, and IGFBP-4 is altered in the SDR kidney. The
relevance of GH status and renal IGFBP-4 and IGFBP-5 mRNA
levels was examined in the present study for the first time. IGF-I
mRNA was shown to be reduced in the SDR kidney and was
normalized by GH treatment, similar to results obtained with
hypophysectomized rats [14, 27], confirming that GH, but not
other pituitary hormones, is responsible for its regulation.
IGFBP-1 and IGFBP-4 mRNA levels were higher in SDRs than in
normal rats, suggesting negative regulation by GH in the former.
GH was effective in reducing the IGFBP-1 mRNA level although
C
r l SDR
expression in kidney of normal SD rats (Normal) and SDRs 48 hours fasting.
it was unable to lower the increased level of IGFBP-4 mRNA. The
reason why increased IGFBP-4 mRNA was not reversed by GH
remains unknown. It has been reported that, in SDR rats, levels of
pituitary prolactin (PRL) and its mRNA are reduced [151and this
has been ascribed to a reduced number of PRL cells in the
anterior pituitary gland [28]. Although it is known that PRL
injection of hypophysectomized rats does not affect renal IGF-I
gene expression [29], we cannot exclude the possibility that PRL
might contribute to the elevation of the IGFBP-4 mRNA level in
the SDR kidney.
It was of interest to note that changes in IGFBP mRNA levels
brought about by GH-modulation are different in liver and
kidney. We have recently shown [10] that hepatic expression of
mRNA encoding IGF-I and IGFBP-3 were reduced and IGFBP-1
mRNA was elevated in SDR. GH administration normalized
these levels, indicating the association of GH but not other
pituitary hormones with hepatic expressions of these genes.
Although IGFBP-2 mRNA was elevated in the SDR liver, GH
administration failed to effect any change nor was there a change
in the expression of IGFBP-4 mRNA [101. These different results
demonstrate altered response of IGFBP mRNA by GH-modula-
tion between liver and kidney. There were similarities, however,
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and these were that IGF-I mRNA decreased and IGFBP-1
mRNA increased with a full return to normal values with GH,
suggesting that GH up-regulates IGF-I and down-regulates
IGFBP-1 in both liver and kidney. These results are in agreement
with those reported by Chin, Zhou and Bond, who demonstrated
by in in situ hybridization that IGF-I and IGFBP-1 mRNA are
both localized in renal medullary thick ascending limbs of Henle's
loops in normal rat kidney where their expression appears to be
inversely regulated, directly or indirectly, by GH [30]. The dem-
onstration of reciprocal changes in IGF-1 versus IGFBP-1 gene
expression in the kidney suggests a local interaction between
IGF-1 and IGFBP-1 in the regulation of their respective mRNA
levels. We have recently shown that tubular hypertrophy induced
by furosemide is associated with an increase in IGFBP-1 mRNA,
but not with an increase in IGF-I mRNA [31]. IGFBP-2,
IGFBP-3, and IGFBP-5 levels in SDR kidney were found to be
similar to those in the normal rats even though there was a
tendency for the IGFBP-5 mRNA level to increase. Although we
cannot exclude the possibility that IGFBP-2, -3, and -5 mRNAs
are regulated at least in part by GH, the major regulatory
mechanism(s) of mRNA expression of these proteins involves
factors which are different from those responsible for the regula-
tion of other IGFBPs examined in this study. IGFBP-3 was
formerly known as the GH-dependent IGF binding protein,
because its presence in serum could be correlated with the
secretory status of GH [32]. Recent evidence, however, suggests
that IGF-I, rather than GH, is a major regulator of IGFBP-3 [26].
In chronic renal failure serum IGFBP-3 increases [33], and
together with other IGFBPs it is well characterized [34]. It has
been shown that in hypophysectomized rats IGFBP-3 mRNA is
elevated in kidney whereas it is reduced in liver with an accom-
panying decrease in the serum level of IGFBP-3, suggesting that
a different pituitary-derived or -dependent factor may be involved
[27].
B
J-
T
1000
900
800
700
600
500
400
300
200
100
0
C F C F
Normal SDR
C F C F
Normal SDR
A
120
100
40
20
0
C
140
120
2 100
Co 800
60
40
20
0
200
150C
:
'::
0
D
•
0
120
100
80
60
PITH40200
C F C F
Normal SDR
C F C F
Normal SDR
C F C F
Normal SDR
C F C F
Normal SDR
Fig. 4. Changes in relative abundance of JGF-I
(A), IGFBP-1 (B), IGFBP-2 (C), IGFBP-3 (D),
IGFBP-4 (E), and IGFBP-5 (F) mRNAs in
normal SD rats (Normal) and SDRs 48 hours
fasting. C, control (normally fed); F, fasted 48
hours. < 0.05 vs. control (normally fed) rats.
Values were corrected based on amount of
actin mRNA.
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With SDRs, we were able to examine the effect of fasting on
kidney IGF-I and IGFBP mRNA levels in a GH-deficient model
without having to consider changes in the serum GH level. In
normal rats, fasting resulted in a decrease in IGF-I mRNA in
association with an increase in IGFBP-1 mRNA. Despite the
reduced level of IGF-I mRNA in the SDR, fasting for 48 hours
resulted in further reduction of IGFBP-1 mRNA. This finding
suggests the presence of other nutrition-sensitive factors involved
in the regulation of IGF-I gene expression both in kidney and in
liver, as previously reported by us [10] and others [351 We can
conclude that the presence of other pituitary hormones does not
alter this nutritional effect. The reduced level of circulating insulin
that occurs with fasting may be responsible for this, since reduc-
tion of hepatic IGF-I mRNA in the diabetic animal can be
restored by insulin injection [36]. The IGFBP-1 mRNA level was
elevated in kidneys of both the SDR and normal rat as a result of
fasting. Although it is known that reduction of GH secretion
during fasting contributes to an increase in hepatic IGFBP-1
mRNA [37], the finding that the IGFBP-1 mRNA level was
likewise elevated in the SDR which has a total lack of GH suggests
the presence of other nutrition-sensitive factor(s) involved in the
regulation of IGFBP-1 gene expression in the kidney. Insulin may
be responsible since the serum IGFBP-1 level is regulated at least
in part by this hormone [38]. Unfortunately, the serum insulin
response to fasting was not measured in the present study. With
respect to mRNA levels of other binding proteins, those of
IGFBP-2, -3, -4, -5 remained unchanged in both normal rats and
SDRs. We have, however, recently reported [10] that, in the SDR
liver, the IGFBP-2 mRNA level increased as a result of fasting as
was the case in normal rats, suggesting that the response of
IGFBP mRNA to fasting differs according to tissue type.
In conclusion, we demonstrated in kidney that GH up-regulated
IGF-I and down-regulated IGFBP-1 mRNA, and that fasting for
48 hours down-regulated IGF-I and up-regulated IGFBP-1
mRNA. We also showed that these changes seemed to be
regulated by other nutrition-sensitive factor(s), such as insulin,
which is in agreement with findings previously reported for liver.
Moreover, with respect to kidney, IGFBP-1 mRNA seems to be
unique among IGFBP mRNAs in being nutritionally sensitive. We
also demonstrated that the IGFBP-4 mRNA level was elevated in
the SDR kidney, although it was unaltered in the SDR liver. The
mechanism(s) involved, however, remains unknown. Compared
with the previous study, the present data suggest that IGFBP
mRNA, particularly that of IGFBPs-2, -3, -4, 5 are regulated
differently in different tissues. Since GH and nutritional status are
associated in the regulation of IGFBPs in the kidney, nutrition-
dependent growth appears to be regulated by the GH-IGF-
IGFBP axsis. Further investigation of the physiological role of
IGFBPs should be undertaken in the future.
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